Skip to main content
OpenTrials
Completed

NCT Number: NCT03491540

Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery

This study aims to demonstrate that a preoperative combination of mechanical bowel preparation and oral antibiotics, before elective laparoscopic rectal cancer surgery, is associated with a reduction of postoperative surgical site infection rate, as compared to mechanical bowel preparation alone Our hypothesis is that a preoperative colonic preparation including a combination of mechanical bowel preparation and oral antibiotics before elective laparoscopic rectal cancer surgery is associated with a reduced rate of 30-day postoperative surgical site infection, as compared to mechanical bowel preparation alone

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Service de chirurgie viscérale, cancérologique / Hôpital Saint-Louis

Paris, Île-de-France Region, 75010, France

About this study

This study aims to demonstrate that a preoperative combination of mechanical bowel preparation and oral antibiotics, before elective laparoscopic rectal cancer surgery, is associated with a reduction of postoperative surgical site infection rate, as compared to mechanical bowel preparation alone.

This study's hypothesis is that a preoperative colonic preparation including a combination of mechanical bowel preparation and oral antibiotics before elective laparoscopic rectal cancer surgery is associated with a reduced rate of 30-day postoperative surgical site infection, as compared to mechanical bowel preparation alone Preoperative mechanical bowel preparation (MBP) has been proposed in an attempt to reduce the colonic fecal load and to limit the risk of surgical site contamination, thus theoretically limiting the risk of postoperative surgical site infection (SSI). However, the benefit of such MBP before colorectal surgery is related to type of procedure performed. Indeed, several randomized controlled trials (RCT) and meta-analyses have demonstrated the absence of benefit of MBP before colon cancer surgery, whereas a recent RCT suggested that MBP before rectal cancer surgery was associated to a significant reduction of postoperative SSI, as compare to the absence of preoperative MBP.

Recent studies suggested that the adjunction of oral antibiotics during MBP could help efficiently reduce the risk of postoperative SSI. Indeed, a recent meta-analysis of RCT have suggested that patients preoperatively receiving both MBP and oral antibiotics were exposed to a significantly reduced risk of postoperative SSI, as compared to patients receiving only preoperative MBP. This result was confirmed in a recent RCT which compared preoperative MBP and oral antibiotics versus MBP alone in a heterogeneous population of patients who underwent laparoscopic colonic or rectal surgery. However, to date, no RCT compared the outcomes of an MBP with oral antibiotics to MBP without oral antibiotics in a homogeneous cohort of patients undergoing rectal cancer surgery.

This study aims to demonstrate that a preoperative combination of mechanical bowel preparation and oral antibiotics, before elective laparoscopic rectal cancer surgery, is associated with a reduction of postoperative surgical site infection rate, as compared to mechanical bowel preparation alone.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18 or more
  • Scheduled to undergo elective restorative laparoscopic cancer of the rectal (<15 cm from the anal margin) with sphincter preservation
  • With Signed consent
  • And affiliated to the French social security system

Exclusion criteria

  • Emergent surgery
  • Scheduled total colo-proctectomy
  • Scheduled abdominoperineal restion with definitive colostomy
  • Scheduled associated concomitant resection of another organ (liver, etc.)
  • Active bacterial infection at the time of surgery or recent antibiotic therapy (up to 15 days before surgery)
  • Associated inflammatory bowel disease
  • Patients with known colonization with multidrug-resistant enterobacteriacea
  • History of allergy or contraindication to the Ornidazole, Gentamycin, X-PREP or to any of the excipients of the drugs used.
  • Cirrhosis of grade B and C (Child-Pugh classification)
  • Myasthenia
  • Allergy to one of the other treatments administered for the purpose of the trial (including betadine)
  • Patient suffering from severe central neurologic diseases, fixed or progressive.
  • Pregnant patients
  • Refusal to participate or inability to provide informed consent

Treatment and study plan

Sennosides colonic preparation

Drug

Mechanical bowel preparation :

Sennosides colonic preparation (X-PREP)

1 per day, on day -2 and day -1

Oral Gentamycin

Drug

Oral gentamycin:

Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials

Oral Ornidazole

Drug

Oral ornidazole :

Ornidazole

1 g per day (2 tablet per day), on day -2 and day -1; In tablets

Oral Placebo Gentamycin

Drug

Placebo for oral gentamycin :

Same presentation as oral gentamycin x4 per day on day -2 and day -1

Oral Placebo Ornidazole

Drug

Placebo for oral ornidazole :

Same presentation as oral ornidazole

1g per day (2 tablets per day) on day -2 and day -1

Primary outcomes

  1. Postoperative 30-day surgical site infection (SSI).

    Time frame: 30 days

    SSI will be defined and classified as superficial, deep and/or organ-space infection on the basis of validated and well-defined criteria developed by the Centers for Disease Control and Prevention (CDC), validated in French by the Comité technique des infections nosocomiales et des infections liées aux soins.

Secondary outcomes

  1. Overall postoperative morbidity

    Time frame: 30 days

    Including all postoperative complications occurring within 30 days after surgery, defined and classified according to the Clavien-Dindo classification.

  2. Severe postoperative morbidity

    Time frame: 30 days

    Including all complications graded 3 or more according to the Clavien-Dindo classification, and occurring within 30 days after surgery.

  3. Postoperative mortality

    Time frame: 30 days

    Including all deaths occurring within 30 days after surgery.

  4. Postoperative anastomotic leakage

    Time frame: 90 days

    Defined as the passing of any intra-colonic content (air, liquid, intestinal content, or radiological contrast) through an anastomosis or by an peri-anastomotic abscess, even in the absence of intra-colonic content leak through the anastomosis, observed in drainages, surgical incision, vagina, during a surgical procedure or on a radiological examination, occurring within 90 days after surgery.

  5. Postoperative length of hospital stay

    Time frame: Up to 90 days

    Calculated from the day of surgery to the day of hospital discharge.

  6. Unplanned hospitalization

    Time frame: 90 days

    Defined as any unplanned hospitalization between surgery and postoperative day 90.

  7. Tolerance of the colonic preparation

    Time frame: The day before surgery

    Evaluated using a dedicated questionnaire performed the evening before surgery.

  8. Clostridium difficile colitis occurrence

    Time frame: 30 days

    Defined as clinical symptoms of clostridium difficile colitis with at least 1 stool sample positive for Clostridium difficile toxin A/B as detected by enzyme-linked immunosorbent assay within 30 days after surgery.

  9. Rate of multi-resistant bacteria carriage

    Time frame: The day before or the day of surgery

    Defined as rate of multi-resistant bacteria carriage

  10. Date of adjuvant chemotherapy beginning

    Time frame: 90 days

    If indicated

  11. Temporary stoma closure rate

    Time frame: 90 days

    Define as temporary stoma closure

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery: a Multi Center Double-Blinded Randomized Controlled Trial (PREPACOL2 Study)

Acronym: PREPACOL2

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Apr 9, 2018
Registry last updated
Jan 5, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.